FDA deepens Vertex's Casgevy label to include patients as young as 2 on July 06, 2026 age 2 Anemia, Sickle Cell Approved Casgevy Clustered Regularly Interspaced Short Palindromic Repeats gene therapy Pediatric brand name United States Food and Drug Administration +
Taking the temperature on new and emerging SCD therapies on May 19, 2026 Anemia, Sickle Cell BCL11A gene canakinumab Casgevy Clustered Regularly Interspaced Short Palindromic Repeats crizanlizumab Fetal Hemoglobin gene therapy hydroxyurea inclacumab Lyfgenia mitapivat voxelotor +
CRISPR Therapeutics Reports Q1 2026 Financial Results with CASGEVY Revenue of $43M and $2.44B Cash Position on May 05, 2026 Casgevy cash position Clustered Regularly Interspaced Short Palindromic Repeats financial results gene-editing therapy net loss +
NHS England Approves Groundbreaking CRISPR Gene Therapy for Sickle Cell Disease on February 03, 2025 Anemia Casgevy Clustered Regularly Interspaced Short Palindromic Repeats England exagamglogene autotemcel gene therapy Nance-Horan syndrome Nitroglycerin/Sodium Citrate/Ethanol Solution Sickle Cell +